Search

Displaying results 1081 - 1090 of 7604 in total
  1. Drug

    Amorolfine

    go.drugbank.com/drugs/DB09056
    ApprovedWithdrawn

    It is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries … It is not approved for the treatment of onychomycosis in the United States or Canada.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  2. Drug

    Nonoxynol-9

    go.drugbank.com/drugs/DB06804
    ApprovedWithdrawn

    It is the most commonly used spermicidal contraceptive in the UK and the USA. In several European countries, spermicides are no longer on the market. … N-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams, gels, foams and condom lubricants.

    Categories: Hormonal Contraceptives for Systemic Use, Contraceptive Agents, Male
  3. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940,L64047] It is the second therapy approved for FOP, following [palovarotene] (Sohonos), which was approved in 2023, and is the first FOP therapy shown to reduce clinician-assessed flare-ups. … [L63940] It is administered by intravenous infusion every four weeks.

  4. Drug

    Vanglusagene ensiparvovec

    go.drugbank.com/drugs/DB17675
    Investigational

    Synonyms: recombinant adeno-associated viral (AAV) vector that contains a bio-engineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of human acid a-glucosidase
  5. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].

  6. Drug

    Aspartic acid

    go.drugbank.com/drugs/DB00128
    ApprovedInvestigationalNutraceutical

    One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

    Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSION
  7. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Meglitnides may have a neutral effect on weight or cause a slight increase in weight.

  8. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    across the globe, including Canada, Mexico, the UK, the EU, and Australia, amongst others. … [L12669] The trial is taking place in the UK, where the vaccine will be administered intramuscularly to healthy adult volunteers between the ages of 18 and 55.[L12669]

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Indication

    Chronic Granulocytic Leukemias

    go.drugbank.com/conditions/DBCOND0143005
    Drugs: Cyclophosphamide
    Synonyms: Chronic myelogenous leukemia, no International Classification of Diseases for Oncology subtype
  10. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.